MA-VERTEX-PHARMA
7.4.2020 15:02:17 CEST | Business Wire | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the Vertex Foundation, a nonprofit charitable foundation, commits to make donations totaling $5 million in 2020 to support global COVID-19 relief efforts, including doubling its match for employees’ charitable donations to eligible organizations responding to the COVID-19 pandemic. The Vertex Foundation’s funds will help organizations that are providing emergency relief and assistance in the global communities where Vertex employees live and work, with a focus on providing health care and supplies and support for vulnerable populations.
“The Vertex Foundation’s immediate priority is to address the unprecedented needs of our local communities resulting from COVID-19. We are focused on providing funding to organizations that can provide immediate access to health care and health supplies — including testing and personal protective equipment — in hard-hit countries, and those who are working on-the-ground to provide vulnerable populations with food, care and education,” said Michael Parini, Chairman of the Vertex Foundation and Executive Vice President and Chief Legal, Administrative and Business Development Officer at Vertex.
Essential Health Care and Health Supplies
The Vertex Foundation today announced that it has committed $1 million to Direct Relief, an organization dedicated to providing essential supplies for health workers, such as critical personal protective equipment, N-95 masks, battery powered oxygen concentrators and ventilators. The Foundation’s donation will help establish Direct Relief’s European relief efforts, including in UK, Spain, France and Germany, and help the organization expand its response in the U.S.
“Direct Relief is deeply grateful to the Vertex Foundation for their generosity in supporting COVID-19 relief efforts in the U.S. and allowing us to ramp up our efforts in Europe,” said Thomas Tighe, Direct Relief President and CEO. “Their significant commitment in this challenging time is greatly appreciated.”
In addition, the Vertex Foundation is also supporting the following organizations to help provide essential health care and health supplies:
- Partners HealthCare in Boston , to support an integrated COVID-19 response including delivering patient testing across the community and through donations of the company’s personal protective equipment;
- CDC Foundation’s Emergency Response Fund , to provide enhanced public health laboratory capacity, develop and deploy technology tools, and support state and local health departments;
- French Red Cross (Croix Rouge) , to support on-the-ground front-line response and humanitarian relief efforts to enhance the government’s response in France;
- Scripps Health Foundation in San Diego , to support their drive-through testing centers and fully fund one center for five weeks; and
- EMERGENCY Ong Onlus in Italy , to provide medical care to the most vulnerable populations in the Lombardy region of Italy, where the crisis is severe.
Support for Vulnerable Populations
Last month, the Vertex Foundation donated $1 million to help establish the Boston Resiliency Fund , which is coordinating fundraising and philanthropic efforts to assist Boston residents whose health and well-being are most immediately impacted by the COVID-19 pandemic.
“The outpouring of support and generosity that we've seen from our private and philanthropic partners as we navigate these difficult times together has been tremendous,” said Mayor Martin J. Walsh. “Jeff Leiden and the Vertex Foundation were instrumental in getting the Boston Resiliency Fund off the ground to support our frontline workers and our residents most in need, and I thank them for their continued efforts and for going above and beyond to support relief efforts for our residents.”
In addition, the Vertex Foundation announced today that it has made additional donations to the following organizations around the world to provide essential community support for vulnerable populations — specifically food, care and education:
- The Trussell Trust in the UK , to support its nationwide network of food banks and provide emergency food and support needed because of COVID-19; to build on and support the development of a national helpline and referral system to enable food banks to meet increased demand for emergency food;
- Crisis in the UK , to help with on-the-ground support for the homeless including “essentials” packages of food, tissues and hand sanitizers;
- Age UK , to support older people, particularly those ages 70 and older, who are worst hit by the pandemic physically and emotionally;
- Caritas in Spain , to provide home delivery of food to elderly and support homeless shelters and health needs in Madrid;
- Les Restos du Coeur in France , to support food distribution to the neediest and provide hygiene products to volunteers distributing the food;
- Cesvi in Italy , to provide at-home health and food to the elderly in Bergamo and Brescia;
- Feeding San Diego , to provide healthy food through emergency food distribution centers and provide food to San Diego students who rely on free meals;
- Community Foundation of Western Massachusetts , to support its COVID-19 Response Fund for the Pioneer Valley;
- The Food Bank of Western Massachusetts , to provide 400,000 meals for its emergency feeding programs across Hampden, Hampshire, Berkshire and Franklin counties; and
- United Way of Greater Fall River , to support its COVID-19 relief and recovery efforts across the Southcoast Massachusetts community.
About The Vertex Foundation
The Vertex Foundation is a nonprofit charitable foundation. It seeks to improve the lives of people with serious diseases and in its communities through education, innovation and health programs. Established in 2017, the Foundation is a long-term source of charitable giving and is part of Vertex Pharmaceuticals’ corporate giving commitment. To learn more about the Vertex Foundation, visit https://www.vrtx.com/responsibility/vertex-foundation .
About Vertex
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of genetic and cell therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.
Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London, UK. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 10 consecutive years on Science magazine's Top Employers list and top five on the 2019 Best Employers for Diversity list by Forbes. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram.
(VRTX-GEN)
View source version on businesswire.com: https://www.businesswire.com/news/home/20200407005509/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mainstay Medical Announces Two-Year Outcomes from RESTORE Clinical Trial of ReActiv8®3.9.2026 22:30:00 CEST | Press release
ReActiv8® Restorative Neurostimulation™ treatment group showed sustained improvements in measures of disability, pain and quality of life from the one-year to the two-year timepoints.83% of control group patients elected to cross over and receive ReActiv8 therapy after the one-year assessment.After one year of ReActiv8 therapy, the outcomes in the crossover group were indistinguishable from the treatment group at the same time point, confirming the effect is reproducible, robust, and not cohort specific. Mainstay Medical Holdings plc today announced the publication of the two-year assessment results from the RESTORE randomized clinical trial of ReActiv8 for the treatment of intractable chronic low back pain. The data show continued improvements in back pain-related disability, pain and quality of life in the ReActiv8 treatment group, and improvements after one year of ReActiv8 therapy in the crossover group that were indistinguishable from the improvements shown by the treatment group
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)3.9.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to thirty-one newly hired non-executive employees. The equity awards were granted on September 1, 2026 and consisted of options to purchase an aggregate of 280,600 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 133,500 shares. The options have an exercise price per share equal to $13.24, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restr
Lenovo Advances Hybrid AI Across New Personal and Enterprise Technology3.9.2026 18:00:00 CEST | Press release
Lenovo announces expanded Lenovo and Motorola Qira experiences and availability, new Yoga, Idea, Think, and Motorola devices, and concepts that explore the next era of more personal, connected technology. Today at Lenovo™ Innovation World during IFA 2026, Lenovo unveiled a new portfolio of personal and enterprise technology, showing how its Hybrid AI strategy is moving from vision to practical experiences across devices, infrastructure, services, and the everyday moments that connect them. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903555953/en/ Lenovo Innovation World at IFA 2026 The announcements bring together Lenovo’s “one personal AI, multiple devices” approach with enterprise technology that helps organizations turn data into insights and value. They span personal AI across PCs, smartphones, tablets, and wearables; creator and consumer devices that adapt to different ways of working and expressing ideas; and bus
Bahrain Signs its Participation Contract for Expo 2030 Riyadh3.9.2026 17:45:00 CEST | Press release
The Kingdom of Bahrain has signed its Participation Contract for Expo 2030 Riyadh, marking a new phase in preparations for its participation in the World Expo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903144412/en/ His Excellency Sheikh Khalifa bin Ahmed Al Khalifa, President of the Bahrain Authority for Culture and Antiquities, and Talal Al-Marri, Chief Executive Officer of Expo 2030 Riyadh, at the ceremony. The agreement provides the formal framework for Bahrain’s participation in Expo 2030 Riyadh, enabling preparations to advance across the key organizational and operational aspects of its presence throughout the six-month event, including the development of its pavilion, programmes and visitor experiences. The Participation Contract was signed in Bahrain by Talal Al-Marri, Chief Executive Officer of Expo 2030 Riyadh, on behalf of Expo 2030 Riyadh, and His Excellency Sheikh Khalifa bin Ahmed Al Khalifa, President
Kaltura and Verimatrix Partner to Strengthen Security for OTT and Cloud TV Services3.9.2026 17:45:00 CEST | Press release
Partnership combines Kaltura's Cloud TV platform with Verimatrix's content protection and anti-piracy solutions, with full migration of customers to be carried out in the coming months. Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903384589/en/ Kaltura (Nasdaq: KLTR), the Agentic Digital Experience company, and Verimatrix (Euronext Paris: VMX), a leading provider of security solutions for a safer connected world, today announced a strategic partnership designed to provide enhanced protection for OTT and Cloud TV services. The partnership brings together Kaltura's scalable Cloud TV platform and Verimatrix's Digital Rights Management (DRM) and security capabilities. The joint solution, as part of Kaltura’s Marketplace, helps Telco’s, broadcasters, and media companies securely deliver premium live and on-demand content across a wide range of devices and operating systems. Demand for advanced content protec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
